PMID: 6966453Jan 1, 1980Paper

Pharmacokinetics of mexiletine in renal insufficiency

Acta cardiologica. Supplementum
G BaudinetA Dressé

Abstract

Mexiletine (Mexitil) is an effective antiarrhythmic drug for the treatment of ventricular dysrhythmias. The therapeutic plasma level is situated between 0.75 and 2 microgram/ml. For concentrations higher than 2 microgram/ml, the percentage of severe side effects is rapidly increasing without improvement of the therapeutic efficacy. The main pharmacokinetics parameters of mexiletine are reviewed in the first part of this publication. Contrary to lidocaine, mexiletine may be administrated orally (or intravenously). It is largely and rapidly distributed in the body. The apparent volume of distribution (Vd) is greater than 500 1. The plasma half-time is 10 to 12 hours in healthy volunteers with a 70% plasma protein fixation. Mexiletine is largely metabolized to conjugates after N-methylation and hydroxylation. In the second part of the work, the influence of renal insufficiency on the plasma half-time of mexiletine has been investigated in 11 patients presenting a creatinine clearance situated between 2 and 38 ml/min. The mean plasma half-time for these patients is 11.1 +/- 1.7 hours after a single i.v. injection of 1.5 mg/kg. This value is comparable to the normal values found in the literature. Our control group containing conval...Continue Reading

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

British Journal of Clinical Pharmacology
D el AllafA Dressé
European Journal of Cardiology
N P CampbellA A Adgey
British Journal of Clinical Pharmacology
N P CampbellR G Shanks
Drug Intelligence & Clinical Pharmacy
B J Schrader, J L Bauman
© 2021 Meta ULC. All rights reserved